Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Ukraine launches 'gradual' operation, action limited |
- Battle over Scottish independence slightly tightens in new poll
- Poland: NATO should send troops to east Europe, ignore Russia's objections
- UPDATE 16-Tennis-Monte Carlo Masters men's singles results
- Scores rescued from sinking South Korean ferry, two dead - officials